Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

ARYx Therapeutics, Inc. (ARYX)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-08Dec-31-07Dec-31-06Dec-31-05
   10-K10-K10-K10-K
Revenues  19.74.24.7-0.7
            Revenue growth  374.4%-12.3%-806.3% 
Cost of goods sold  0.20.32.1-28.2
Gross profit  19.53.92.627.5
            Gross margin  98.8%93.7%55.3%-4098.1%
Selling, general and administrative  9.87.76.95.7
Research and development  40.125.024.022.5
EBITDA   [+]-29.3-27.8-27.5-27.6
            EBITDA margin  -148.7%-668.4%-579.4%4114.0%
Depreciation and amortization  1.11.00.80.6
EBIT   [+]-30.4-28.8-28.3-28.2
            EBIT margin  -154.2%-692.6%-596.9%4198.1%
Pre-tax income  0.00.00.00.0
Income taxes  0.00.00.00.0
            Tax rate  0.0%0.0%0.0%0.0%
Net income  0.00.00.00.0
            Net margin  -0.2%-0.7%-0.6%4.2%
   
Basic EPS   [+]($1,646.17)($8,237.00)($26,844.79)($30,729.67)
Diluted EPS   [+]($1,646.17)($8,237.00)($26,844.79)($30,729.67)
   
Shares outstanding (basic)   [+]0.00.00.00.0
Shares outstanding (diluted)   [+]0.00.00.00.0
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy